Have COVID-19 affected ALL epidemiology?

Abstract

Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer in the Nordic countries with an incidence of approximately 4.0 per 100.000 children per year.1 An incidence peak is found in the two to seven years age group with a peak at three years of age, where the incidence is up to 10 times higher than in infancy or among adolescent. Almost eighty per cent of the B-cell precursor (BCP) ALL cases, which constitutes the age-related incidence peak, harbour either an ETV6/RUNX1-translocation or a high-hyperdiploid leukaemic clone.2 Both these subsets are frequently initiated prenatally and 5% of newborns may harbour preleukaemic cells in their cord blood,3, 4 which emphasises their long subclinical phase. A small proportion of ALL cases can be attributed to a strong genetic predisposition,5 while the vast majority are caused by a complex interaction between common germline variants,6, 7 environmental factors such as infections and random events due to the massive expansion of our immune system in early life. Infectious exposures in early life and the associated modulation of our microbiome structure promote normal immune system maturation8 and may accelerate the disappearance of preleukaemic cells and thus influence the subsequent risk of ALL,9, 10 while infections that induce a strong proliferative immune response on the other hand could lead to overt leukaemia.3 An increased incidence of childhood infections in general has been observed during the months prior to the diagnosis of ALL,11 but whether this reflects infection-induced proliferation of a dormant preleukaemic cell population or a leukaemia-induced immune deficiency (reverse causality) is unknown. In industrialised countries, febrile infections in children frequently lead to prescription of antibiotics and the associated disturbance of the gut microbiome could also promote leukaemia development as recently supported by leukaemia-prone murine models.12 In this issue of Acta Pædiatrica, Jarvis and co-workers present observational data indicating a significant reduction in the incidence of childhood ALL in the Oslo region (South-Eastern Norway; ~2.6 million inhabitants) during the Norwegian lockdown response to the COVID-19 pandemic.13 Thus, during the first six months of 2020 only three cases (including two in early March) were diagnosed, with no cases during the four months from March 13th to July 12th, which is significantly below the expected ALL incidence based on historical data (P < .001). During the same time period, the authors also observed a drop in airway pathogens found by PCR, although the number of performed tests did not change markedly compared to historical data. As the COVID-19 challenge to health care systems worldwide is influenced by the magnitude of the spread and the local healthcare resources, referral of childhood cancer patients has been reported being stalled in very challenged regions with more advanced disease being diagnosed later by some. In this context, the paper by Jarvis et al is of interest, as the health care system in Norway, was never seriously burdened by COVID-19 to the same extent as many other healthcare regions in Europe and the US and also due to the free access to health care in Norway. Thus, a reduced number of diagnosed ALL cases in Oslo could potentially reflect a real change in incidence. Such a reduction in ALL incidence has similarly been reported in Hongkong during the SARS epidemic in 2003, while flu epidemics have been associated with sharp peaks in cases of ALL in the United Kingdom.14 Still, the data reported by Jarvis et al need to be interpreted very cautiously: Kjeld Schmiegelow: Speaker and/or Advisory Board Honoraria from Jazz Pharmaceuticals (2020) and Servier (2020); speaker fee from Amgen (2020) and Medscape (2020); Educational grant from Servier (2020).